Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma - PubMed (original) (raw)

Randomized Controlled Trial

Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma

Michele Miraglia Del Giudice et al. Ital J Pediatr. 2017.

Abstract

Background: Allergic rhinitis (AR) and allergic asthma are caused by an IgE-mediated inflammatory reaction. Probiotics may exert anti-inflammatory and immune-modulatory activity. Thus, this study aimed at investigating whether a Bifidobacteria mixture could be able to relieve nasal symptoms, and affect quality of life (QoL) in children with AR and intermittent asthma due to Parietaria allergy.

Materials and methods: The present study was conducted as placebo-controlled, double-blinded, and randomized. Globally, 40 children (18 males; mean age 9 ± 2.2 years) were enrolled. They were treated with probiotics or placebo: 1 sachet/day for 4 weeks. AR symptoms, and QoL were assessed at baseline and after treatment. Use of rescue medications, such as cetirizine syrup and salbutamol spray, was also permitted and recorded.

Results: Children treated with probiotic mixture achieved a significant improvement of symptoms (p < 0.005), and QoL ((p < 0.001). Placebo group had worsening of symptoms (p < 0.005) and QoL (p < 0.001). The use of rescue medications was overlapping in the two groups. The intergroup analysis showed that probiotic mixture was significantly superior than placebo for all parameters.

Conclusions: The current study demonstrated that a Bifidobacteria mixture was able of significantly improving AR symptoms and QoL in children with pollen-induced AR and intermittent asthma.

Clinical trial registration: ClinicalTrials.gov ID NCT02807064 .

Keywords: Allergic rhinitis; Bifidobacteria; Children; Intermittent asthma; Probiotic; Quality of life.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Total symptom scores in patients treated with Placebo (Group A) or Bifidobacteria mixture (Group B) at baseline (T0) and after treatement (T1). Data are expressed as medians, IQR, and standard deviations

Fig. 2

Fig. 2

QoL = practical problems item in patients treated with Placebo (Group A) or Bifidobacteria mixture (Group B) at baseline (T0) and after treatement (T1). Data are expressed as medians, IQR, and standard deviations

Similar articles

Cited by

References

    1. Settipane RA, Schwindt C. Chapter 15: Allergic rhinitis. Am J Rhinol Allergy. 2013;27(Suppl 1):S52–5. doi: 10.2500/ajra.2013.27.3928. - DOI - PubMed
    1. Dondi A, Tripodi S, Panetta V, Asero R, DiRienzo-Businco A, Bianchi A, et al. Italian Pediatric Allergy Network (I-PAN). Pollen-induced allergic rhinitis in 1360 Italian children: comorbidities and determinants of severity. Pediatr Allergy Immunol. 2013;24:742–51. doi: 10.1111/pai.12136. - DOI - PubMed
    1. Global Initiative for Asthma. GINA guidelines. Global strategy for Asthma Management and Prevention. Available at: htpp://www.ginasthma.org/. Accessed July 2016.
    1. Alroqi FJ, Chatila TA. T Regulatory Cell Biology in Health and Disease. Curr Allergy Asthma Rep. 2016;16:27. doi: 10.1007/s11882-016-0606-9. - DOI - PMC - PubMed
    1. Miraglia Del Giudice M, Marseglia A, Leonardi S, La Rosa M, Salpietro C, et al. Allergic rhinitis and quality of life in children. Int J Immunopathol Pharmacol. 2011;24:25–28. doi: 10.1177/03946320110240S406. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources